Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing ...

Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b ...

GeneDx will pay up to $33 million in cash upon the deal's expected closing this quarter. GeneDx could spend up to $51 million ...

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA clearance with its treatment for ...

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target autoimmune diseases via B cell depletion.